COVID-19 vaccine study is finally published after CDC journal blocked it

A COVID-19 vaccine effectiveness study that was blocked from publication in the CDC’s Morbidity and Mortality Weekly Report has now been published in JAMA Network Open, giving the months-long dispute a peer-reviewed landing spot and reviving questions about how the paper was handled inside federal health agencies.

The study’s publication on June 23, 2026, is the latest development in a controversy that began in March, when the paper had been scheduled for MMWR release but was later delayed and then stopped. AP reported that the study found about 55% effectiveness against COVID-19-associated hospitalization and about a 50% reduction in emergency department and urgent care visits.

What the study found

The analysis adds to the evidence base on how COVID-19 vaccines performed in real-world settings. According to AP’s reporting on the newly published paper, the study estimated meaningful protection against severe illness requiring hospitalization, as well as a lower risk of emergency and urgent care visits related to COVID-19.

Those figures are central to why the paper drew attention when it was blocked from the CDC journal. Supporters of publication argued that the findings belonged in the public scientific record, especially because the data speak to current vaccine effectiveness rather than a historical debate.

How the dispute began

Washington Post reporting in April said the paper had been slated for MMWR publication on March 19 before the process was interrupted. AP later reported that U.S. health officials had decided not to publish the study in the CDC journal.

The disagreement quickly became more than a routine editorial question. It turned into a test case for how scientific manuscripts move through the CDC and what happens when leadership objects to the way a study is built or presented.

HHS spokesperson Andrew Nixon said the MMWR’s editorial assessment identified methodological concerns and that the manuscript was not accepted for publication. That explanation differs from reporting that the paper had already been moving toward publication before the decision changed.

The methodology question

At the center of the debate is the study’s observational, or test-negative, design. That method compares vaccinated and unvaccinated people who seek care for similar symptoms, and it is widely used in vaccine research.

Researchers and former officials said the approach is standard in vaccine effectiveness studies, including prior influenza work and earlier COVID-19 analyses. Critics of the blockage argued that the methodology itself was not unusual enough to justify keeping the paper out of MMWR.

The publication in JAMA Network Open does not settle that methodological argument. It does, however, allow outside researchers and readers to evaluate the paper directly rather than relying on secondhand descriptions of the blocked manuscript.

Why the publication matters

The study’s appearance in a peer-reviewed journal matters because CDC publications are closely watched for both scientific and policy signals. When a paper on vaccine effectiveness is blocked inside the federal public health system, questions arise not only about the analysis but also about whether political or bureaucratic considerations shaped the outcome.

That concern is part of why the paper drew strong reaction once it resurfaced in another journal. The episode has been folded into broader worries about the independence of CDC scientific publishing and the way vaccine evidence is communicated to the public.

The stakes extend beyond one manuscript. Vaccine effectiveness estimates influence how researchers, clinicians and the public understand current protection against severe disease and whether messaging from federal health agencies is being filtered through non-scientific pressure.

What remains unclear

One open question is whether the JAMA Network Open version is identical to the manuscript that had been blocked from MMWR. Another is whether CDC or HHS issued any additional public statement after the paper appeared online.

The available reporting also does not fully resolve the exact sequence inside the CDC review process, including how the manuscript moved from internal review to a publication stop. Those unresolved details matter because they go to the heart of the dispute over whether the paper was rejected on scientific grounds or halted for broader reasons.

What is now clear is that the study is public, peer reviewed and available for scrutiny. That gives researchers a chance to assess the data, the design and the conclusions directly, even as debate continues over why the paper did not reach publication in the CDC journal.

The episode has also become part of a wider discussion about vaccine policy and scientific communication at CDC and HHS under Robert F. Kennedy Jr. and CDC director Jay Bhattacharya. For now, the publication of the study ensures the evidence can be examined in the open, while the process that blocked it remains a live issue.